跳至主要内容
临床试验/NCT01782911
NCT01782911已完成不适用

Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients Undergoing IVF Treatment.

IVI Madrid1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2013年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
10
试验地点
1
主要终点
Effect of resveratrol on oocyte quality

研究概览

简要总结

Polycystic ovary syndrome (PCOS) is characterized by enlarged ovaries, menstrual irregularity and hyperandrogenism and is the most common cause of oligoovulatory infertility. Insulin resistance with resulting hyperinsulinemia is also common among women with PCOS, along with increased risk for dyslipidemia, hypertension, diabetes and related cardiovascular consequences. Resveratrol is a natural polyphenol with anti-carcinogenic, anti-proliferative and pro-apoptotic properties, that has been shown to decrease proliferation and steroidogenesis in theca cells, emerging as a potential therapeutic agent in PCOS patients. However, little is known about its potential beneficial effect on oocyte quality as well as other reproductive outcomes, such as implantation an pregnancy rates. The present study evaluates effects of resveratrol on selected biochemical parameters and reproductive outcome among patients with PCOS who undergo in vitro fertilization (IVF).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •Women aged from 18 to 40 years old.
  • •PCOS diagnosis (according to Rotterdam criteria).
  • •Mild or moderate male factor, tubal factor or unknown infertility.

排除标准

  • •Follicle stimulation hormone (third of day of menstruation) > 10 milli international units/L.
  • •Endometriosis (III o IV).
  • •Congenital adrenal hyperplasia.
  • •Cushing syndrome.
  • •Hyperprolactinemia.
  • •Thyroid disease.
  • •Androgenic hormone secretor tumors.
  • •Patients included in this trial did not take either oral contraceptives, steroids or other medications that could modify the ovarian function, insulin sensitivity or lipid metabolism 3 months before the onset of the trial.
  • •Severe male factor (sperm concentration < 5 mill/ml).
  • •Patients undergoing oocyte vitrification to avoid hyperstimulation syndrome will be excluded.

研究组 & 干预措施

Control

Placebo Comparator

Patients will be given pills lacking medication from the onset of menses until the ovum pick-up.

干预措施: Placebo pills (Dietary Supplement)

Resveratrol

Experimental

Patients will be given 2 g of resveratrol a day from the onset of menses until ovarian pick-up.

干预措施: Resveratrol (Dietary Supplement)

结局指标

主要结局

Effect of resveratrol on oocyte quality

时间窗: 40 days

次要结局

  • Effect of resveratrol on testosterone levels.(40 days)
  • Effects of resveratrol on the fertilization rate.(40 days)
  • Effects of resveratrol on the pregnancy rate.(40 days)
  • Effects of resveratrol on inflammatory markers(40 days)

研究者

发起方
IVI Madrid
申办方类型
Other
责任方
Principal Investigator
主要研究者

Juan A Garcia-Velasco

Medical Doctor

IVI Madrid

研究点 (1)

Loading locations...

相似试验